CRISPR Therapeutics AG (CRSP)
97.00
-1.70 -1.72%
NASDAQ
Oct 15, 16:00
97.52
+0.52 +0.54%
After-Hours: 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 901.76M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 5.09 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 446.58M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | 84.29% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 7.392B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 7.985 |
| PE Ratio | 19.06 |
| Price to Book Value | 2.839 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | 778.55M |
| Return on Equity | Upgrade |
View All CRSP News
News
-
WireHeadlineTime (ET)
-
Yahoo10/16 07:00
-
Yahoo10/16 06:25
-
Yahoo10/15 10:11
-
Yahoo10/15 07:47
-
Yahoo10/14 09:40
-
MT Newswires10/14 07:25
-
Globe Newswire10/14 07:00
-
Yahoo10/13 16:12
-
SA Breaking News10/13 15:35
-
Yahoo10/13 12:42
-
MT Newswires10/13 12:13
-
Yahoo10/13 10:52
-
Yahoo10/13 10:08
-
MT Newswires10/13 09:17
-
Yahoo10/13 09:01
-
Yahoo10/13 08:21
-
Yahoo10/13 07:54
-
Yahoo10/13 07:27
-
Yahoo10/13 06:25
-
SA Breaking News10/12 17:51
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 10/28/2021 | Earnings Results | Q3 2021 Earnings Results |
| 07/29/2021 | Earnings Results | Q2 2021 Earnings Results |
| 06/10/2021 02:00 EST | AGM | 2021 Annual General Meeting |
| 04/27/2021 | Earnings Results | Q1 2021 Earnings Results |
| 02/16/2021 | Earnings Results | Q4 2020 Earnings Results |
| 10/28/2020 | Earnings Results | Q3 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.
- URL: http://www.crisprtx.com
- Investor Relations URL: http://ir.crisprtx.com/
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Value
- Next Earnings Release: Oct. 28, 2021
- Last Earnings Release: Jul. 29, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 97.00 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| NEXTX | Shelton Green Alpha | 4.01% |
| IDNA | iShares Genomics Immnlgy & Hlthcr ETF | 3.33% |
| ARKG | ARK Genomic Revolution ETF | 3.01% |
| DSGFX | Delaware Small Cap Growth R | 2.97% |
| ARKK | ARK Innovation ETF | 2.86% |
| ADNRX | American Beacon ARK Transfmt Innov R6 | 2.62% |
| F000010GK1 | JNL/Loomis Sayles Global Growth A | 2.33% |
| HQL | Tekla Life Sciences Investors | 1.68% |
| RYCFX | Rydex Biotechnology C | 1.52% |
| BBH | VanEck Biotech ETF | 1.52% |
| HQH | Tekla Healthcare Investors | 1.48% |
| PJHRX | PGIM Jennison Health Sciences R | 1.40% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- CRSP Tweets Stocktwits
Advertisement
